Emergent Biosolutions (NYSE:EBS) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Emergent Biosolutions Inc. (NYSE:EBS) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $9.46 and traded as high as $12.60. Emergent Biosolutions shares last traded at $12.1760, with a volume of 669,411 shares trading hands.

Analyst Ratings Changes

A number of equities analysts recently commented on EBS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Wall Street Zen upgraded shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Finally, Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Trading Down 1.7%

The firm’s 50-day moving average price is $11.61 and its 200 day moving average price is $9.46. The company has a market cap of $639.48 million, a price-to-earnings ratio of 9.37 and a beta of 2.30. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.18. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The business had revenue of $231.10 million during the quarter, compared to analysts’ expectations of $203.67 million. As a group, equities analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Buying and Selling

In related news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the transaction, the director directly owned 98,417 shares of the company’s stock, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors have recently modified their holdings of the company. Silver Oak Securities Incorporated bought a new stake in Emergent Biosolutions during the 3rd quarter worth approximately $941,000. Wolverine Asset Management LLC boosted its position in shares of Emergent Biosolutions by 28.3% during the second quarter. Wolverine Asset Management LLC now owns 174,933 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 38,600 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after buying an additional 121,583 shares in the last quarter. Geode Capital Management LLC raised its position in Emergent Biosolutions by 108.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock valued at $8,162,000 after buying an additional 666,708 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Emergent Biosolutions during the 2nd quarter valued at $227,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.